D. Danforth

The correlation between human plasma melatonin levels and urinary 6-hydroxymelatonin excretion.

S. Markey, D. Danforth, L. Tamarkin, 1985, Clinica chimica acta; international journal of clinical chemistry.

Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer.

M. Lippman, A. Lichter, D. Danforth, 1982, Science.

Elevated plasma proglucagon-like component with a glucagon-secreting tumor. Effect of streptozotocin.

T. Triche, J. Doppman, R. Beazley, 1976, The New England journal of medicine.

Plasma immunoreactive glucagon fractions in four cases of glucagonoma: Increased “Large glucagon — immunoreactivity”

S. Bhathena, L. Recant, D. Danforth, 1976, Diabetologia.

Plasma melatonin and the hormone-dependency of human breast cancer.

J. Mulvihill, L. Tamarkin, D. Danforth, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormone receptors in malignancy.

D. Danforth, D. Danforth, 1992, Critical reviews in oncology/hematology.

Melatonin-induced increase in cytoplasmic estrogen receptor activity in hamster uteri.

L. Tamarkin, D. Danforth, M. Lippman, 1983, Endocrinology.

Melatonin and malignant disease.

L. Tamarkin, O. Almeida, D. Danforth, 1985, Ciba Foundation symposium.

Breast Cancer Research and Treatment 2001 Reviewers

D. Berry, L. Holmberg, D. Alberts, 2004, Breast Cancer Research and Treatment.

Level of axillary involvement by lymph node metastases from breast cancer is not an independent predictor of survival.

M. Merino, D. Venzon, L. Gerber, 1991, Archives of surgery.

Fluctuations in weight, hematocrit and plasma protein with the menstrual cycle.

D. Danforth, S. Graff, P. K. Boyer, 1946, Endocrinology.